By Debra Kamin
It’s morning in Nahariya, a tiny Israeli town near the Lebanese border, and 4-year-old Benjamin is repeatedly smashing his head against the wall. He spins wildly in circles, screeching at full volume. As his mother tries frantically to calm him, he pulls down his pants and defecates on the floor.
When they leave their apartment, Benjamin wrestles free of her hand and nearly runs into oncoming traffic. Sharon attempts a trip to the supermarket but leaves before she finishes shopping because her son is screaming while he picks up items and throws them to the floor.
That was in October 2016, and typical of most days at the time. Sharon, a single mother who moved to Israel from the United States one year earlier, was alone and losing control. Benjamin was taking Ritalin, a drug usually associated with attention deficit hyperactivity disorder (ADHD), which he did not have. He’d also tried the antipsychotic ziprasidone and a mix of antidepressants and anti-anxiety drugs. None of them helped, and he often became more hyperactive as they wore off.
All that changed a year ago, when Benjamin started taking marijuana. In the little apartment he shares with his mother, mornings are now relaxed and orderly. His transformation may signal the arrival of a long-awaited and desperately needed healing for the many others just like him: children living with severe autism.
Read more at Newsweek